Cantor Fitzgerald initiated coverage on ObsEva with a new price target
$OBSV
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of ObsEva with a rating of Overweight and set a new price target of $6.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/30/2022 | Buy → Neutral | H.C. Wainwright | |
| 6/3/2022 | $6.00 | Overweight | Cantor Fitzgerald |
| 4/26/2022 | $12.00 | Buy | Canaccord Genuity |
| 3/28/2022 | $12.00 | Buy | Aegis Capital |
| 11/29/2021 | $17.00 → $15.00 | Buy | HC Wainwright & Co. |
ObsEva Files Year End 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 31, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF), a biopharmaceutical company developing and commercializing novel therapies to improve women's health, today published its U.S. Annual Report on Form 10-K for Fiscal Year 2022, including the U.S. GAAP financial results for year-end 2022. The U.S. Annual Report on Form 10-K can be accessed in the financial section of the Company's website, here or directly via the link here. ObsEva expects to publish its Swiss Annual Report to Shareholders, including the financial results for year end 20
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") on March 14, 2023, advising the Company that its securities are scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of U.S. business on March 23, 2023. A Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing and registration on Nasd
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy. It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. Additionally, the Company announced the appointment of Fabien de Ladonchamps as Chief
H.C. Wainwright downgraded ObsEva from Buy to Neutral
Cantor Fitzgerald initiated coverage of ObsEva with a rating of Overweight and set a new price target of $6.00
Canaccord Genuity initiated coverage of ObsEva with a rating of Buy and set a new price target of $12.00